ImmunityBio (IBRX) Invested Capital (2013 - 2026)
ImmunityBio (IBRX) reported Invested Capital of -$389.1 million for Q1 2026, down 355.21% year-over-year from $152.5 million in Q1 2025, and down 1.68% on a QoQ basis from -$382.7 million in Q4 2025.
ImmunityBio (IBRX) has 14 years of Invested Capital data on file, last reported at -$389.1 million in Q1 2026.
- Quarterly Invested Capital fell 355.21% year-over-year to -$389.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$389.1 million (down 355.21% YoY) and the FY2025 annual result came in at -$382.7 million, down 288.17% from the prior year.
- Invested Capital eased to -$389.1 million in Q1 2026 per IBRX's latest filing, from -$382.7 million in the prior quarter.
- Across five years, Invested Capital topped out at $203.4 million in Q4 2024 and bottomed at -$645.2 million in Q2 2023.
- The 5-year median for Invested Capital is -$389.1 million (2026), against an average of -$364.3 million.
- The widest annual swing landed in 2024, when Invested Capital jumped 152.7%; it then plunged 355.21% in 2026.
- Tracing IBRX's Invested Capital over 5 years: stood at -$395.7 million in 2022, then rose by 2.46% to -$385.9 million in 2023, then jumped by 152.7% to $203.4 million in 2024, then tumbled by 288.17% to -$382.7 million in 2025, then decreased by 1.68% to -$389.1 million in 2026.
- Per Business Quant, the three latest IBRX Invested Capital figures stand at -$389.1 million (Q1 2026), -$382.7 million (Q4 2025), and -$387.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -389.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -389.13 Mn |
| Dec 31, 2025 | -382.70 Mn |
| Sep 30, 2025 | -387.10 Mn |
| Jun 30, 2025 | -64.82 Mn |
| Mar 31, 2025 | -85.48 Mn |
| Dec 31, 2024 | 203.38 Mn |
| Sep 30, 2024 | -386.19 Mn |
| Jun 30, 2024 | -588.57 Mn |
| Mar 31, 2024 | -584.35 Mn |
| Dec 31, 2023 | -385.94 Mn |
| Sep 30, 2023 | -410.65 Mn |
| Jun 30, 2023 | -645.18 Mn |
| Mar 31, 2023 | -501.72 Mn |
| Dec 31, 2022 | -395.69 Mn |
| Sep 30, 2022 | -429.08 Mn |
| Jun 30, 2022 | -421.97 Mn |
| Mar 31, 2022 | -337.56 Mn |
| Dec 31, 2021 | -243.91 Mn |
| Sep 30, 2021 | -181.25 Mn |
| Jun 30, 2021 | -141.87 Mn |
| Mar 31, 2021 | -167.52 Mn |
| Dec 31, 2020 | -103.65 Mn |
| Sep 30, 2020 | -49.72 Mn |
| Jun 30, 2020 | 16.61 Mn |
| Mar 31, 2020 | -19.84 Mn |
| Dec 31, 2019 | 16.81 Mn |
| Sep 30, 2019 | 136.82 Mn |
| Jun 30, 2019 | 152.23 Mn |
| Mar 31, 2019 | 169.34 Mn |
| Dec 31, 2018 | 83.64 Mn |
| Sep 30, 2018 | 164.26 Mn |
| Jun 30, 2018 | 183.44 Mn |
| Mar 31, 2018 | 202.82 Mn |
| Dec 31, 2017 | 221.21 Mn |
| Sep 30, 2017 | 239.69 Mn |
| Jun 30, 2017 | 252.92 Mn |
| Mar 31, 2017 | 280.49 Mn |
| Dec 31, 2016 | 295.17 Mn |
| Sep 30, 2016 | 312.74 Mn |
| Jun 30, 2016 | 329.08 Mn |
| Mar 31, 2016 | 346.17 Mn |
| Dec 31, 2015 | 357.35 Mn |
| Sep 30, 2015 | 362.75 Mn |
| Jun 30, 2015 | 126.58 Mn |
| Dec 31, 2014 | 57.77 Mn |
| Dec 31, 2013 | -3.76 Mn |